Yayın:
Changes in the management of type 2 diabetic patients in family medicine practices in the Bursa region

dc.contributor.buuauthorGöktaş, Olgun
dc.contributor.buuauthorGül, Özen Öz
dc.contributor.buuauthorErtürk, Erdinç
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentEndokrinoloji ve Metabolizma Ana Bilim Dalı
dc.contributor.departmentİç Hastalıkları Bölümü
dc.contributor.departmentAile Hekimliği Ana Bilim Dalı
dc.contributor.researcheridAAJ-6536-2021
dc.contributor.researcheridAAI-1005-2021
dc.contributor.scopusid6603078279
dc.contributor.scopusid26040787100
dc.contributor.scopusid7005488796
dc.date.accessioned2023-08-29T06:17:11Z
dc.date.available2023-08-29T06:17:11Z
dc.date.issued2017-04
dc.description.abstractAim: The aim of the study was to investigate the treatment and monitoring patterns of type 2 diabetes patients in the Bursa region over the last 5 years since the implementation of family practice in Turkey in 2010. Methods: A total of 216 volunteer family doctors working in family health centers took part in this study. The records of 44,819 diabetic patients who visited these doctors between January 1, 2010 and December 31, 2014 were inspected retrospectively. Apart from the identity of the patients, morphometric data, including the type of medication used for diabetes and the HbA1C, serum creatinine and LDL cholesterol values, were recorded. Results: A total of 38.9% (17,416 patients) of the patients in the study were male and 61.1% (27,403 patients) were female. The average age was 59.7 years with a range of 13.2 years. Although the patients' average body mass index (BMI) did not change over the 5 years monitoring, average blood pressure (BP), and serum creatinine and LDL cholesterol levels decreased significantly. The hemoglobin A1c levels were significantly lower after 2010 compared to the 2010 data. Upon examining the medication prescribed for the patients, we determined that the use of metformin and insulin increased, whereas the prescription of thiazolidinedione (glitazone) decreased. There was a significant increase in the amount of patient data recorded over the last 5 years. Conclusions: Despite the increased level of data entry in these patients with type 2 diabetes, the surveillance of diabetes parameters according to treatment guidelines remains suboptimal. There continues to be a need to engage family practitioners on ongoing education and practice enhancement programs.
dc.identifier.citationGöktaş, O. vd. (2017). ''Changes in the management of type 2 diabetic patients in family medicine practices in the Bursa region''. Primary Care Diabetes, 11(2), 178-183.
dc.identifier.doi10.1016/j.pcd.2016.10.004
dc.identifier.endpage183
dc.identifier.issn1751-9918
dc.identifier.issn1878-0210
dc.identifier.issue2
dc.identifier.pubmed27852516
dc.identifier.scopus2-s2.0-85008174113
dc.identifier.startpage178
dc.identifier.urihttps://doi.org/10.1016/j.pcd.2016.10.004
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1751991816301073
dc.identifier.urihttp://hdl.handle.net/11452/33658
dc.identifier.volume11
dc.identifier.wos000396955300011
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherElsevier
dc.relation.journalPrimary Care Diabetes
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectEndocrinology & metabolism
dc.subjectGeneral & internal medicine
dc.subjectDiabetes mellitus
dc.subjectFamily medicine
dc.subjectMonitoring of diabetes
dc.subjectTreatment of diabetes
dc.subjectBursa-Turkey
dc.subjectEuropean association
dc.subjectPrescribing trends
dc.subjectHyperglycemia
dc.subjectStatement
dc.subjectCare
dc.subject.emtreeAcarbose
dc.subject.emtreeAntidiabetic agent
dc.subject.emtreeCreatinine
dc.subject.emtreeDipeptidyl peptidase IV inhibitor
dc.subject.emtreeGlitazone derivative
dc.subject.emtreeGlucose
dc.subject.emtreeHemoglobin A1c
dc.subject.emtreeInsulin
dc.subject.emtreeLow density lipoprotein cholesterol
dc.subject.emtreeMeglitinide
dc.subject.emtreeMetformin
dc.subject.emtreeSulfonylurea derivative
dc.subject.emtreeAntidiabetic agent
dc.subject.emtreeBiological marker
dc.subject.emtreeGlycosylated hemoglobin
dc.subject.emtreeHemoglobin A1c protein
dc.subject.emtreeHuman
dc.subject.emtreeAdult
dc.subject.emtreeArticle
dc.subject.emtreeBlood pressure monitoring
dc.subject.emtreeBody mass
dc.subject.emtreeCholesterol blood level
dc.subject.emtreeCreatinine blood level
dc.subject.emtreeDrug use
dc.subject.emtreeFamily medicine
dc.subject.emtreeFemale
dc.subject.emtreeGeneral practice
dc.subject.emtreeGeneral practitioner
dc.subject.emtreeGlucose blood level
dc.subject.emtreeHemoglobin blood level
dc.subject.emtreeHuman
dc.subject.emtreeInsulin treatment
dc.subject.emtreeMajor clinical study
dc.subject.emtreeMale
dc.subject.emtreeMedical record review
dc.subject.emtreeMiddle aged
dc.subject.emtreeMorphometry
dc.subject.emtreeNon insulin dependent diabetes mellitus
dc.subject.emtreePatient monitoring
dc.subject.emtreePrescription
dc.subject.emtreePriority journal
dc.subject.emtreeTurkey (republic)
dc.subject.emtreeAged
dc.subject.emtreeBlood
dc.subject.emtreeClinical practice
dc.subject.emtreeDrug effects
dc.subject.emtreeGeneral practice
dc.subject.emtreeGlucose blood level
dc.subject.emtreeHealth care disparity
dc.subject.emtreeMetabolism
dc.subject.emtreeNon insulin dependent diabetes mellitus
dc.subject.emtreePractice guideline
dc.subject.emtreeProtocol compliance
dc.subject.emtreeRetrospective study
dc.subject.emtreeTime factor
dc.subject.emtreeTreatment outcome
dc.subject.emtreeTrends
dc.subject.meshAged
dc.subject.meshBiomarkers
dc.subject.meshBlood glucose
dc.subject.meshDiabetes mellitus, type 2
dc.subject.meshFamily practice
dc.subject.meshFemale
dc.subject.meshGlycated hemoglobin A
dc.subject.meshGuideline adherence
dc.subject.meshHealthcare disparities
dc.subject.meshHumans
dc.subject.meshHypoglycemic agents
dc.subject.meshMale
dc.subject.meshMiddle aged
dc.subject.meshPhysicians, family
dc.subject.meshPractice guidelines as topic
dc.subject.meshPractice patterns, physicians
dc.subject.meshRetrospective studies
dc.subject.meshTime factors
dc.subject.meshTreatment outcome
dc.subject.meshTurkey
dc.subject.scopusAntidiabetic Agent; Biguanide Derivative; Hypoglycemic Agents
dc.subject.wosEndocrinology & metabolism
dc.subject.wosPrimary health care
dc.titleChanges in the management of type 2 diabetic patients in family medicine practices in the Bursa region
dc.typeArticle
dc.wos.quartileQ4 (Endocrinology & metabolism)
dc.wos.quartileQ3 (Primary health care)
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Aile Hekimliği Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/İç Hastalıkları Ana Bilim Dalı.
local.indexed.atPubMed
local.indexed.atScopus
local.indexed.atWOS

Dosyalar

Lisanslı seri

Şimdi gösteriliyor 1 - 1 / 1
Placeholder
Ad:
license.txt
Boyut:
1.71 KB
Format:
Item-specific license agreed upon to submission
Açıklama